{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:18:17Z","timestamp":1762161497380,"version":"3.44.0"},"reference-count":7,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,4,15]]},"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>In addition to the TRANSFORMS, FREEDOMS, INFORMS studies, very few publications have identified new cases of skin cancer in patients treated with fingolimod. Here, we present the case of a 52-year-old Caucasian patient with relapsing remitting multiple sclerosis for 19 years, with a phototype II with blue eyes, light brown hair, no personal or family history of melanoma and a low number of naevi (&lt;10). She did not experience intense sun exposure in childhood as well as severe sunburn and did not practise sessions in ultraviolet cabins. This case is distinguished from other published cases, usually superficial spreading malignant melanoma by its unclassifiable histological character. The occurrence of skin cancers in patients with multiple sclerosis remains exceptional, but new cases have recently emerged requiring the strengthening of dermatological follow-up of such patients.<\/jats:p>","DOI":"10.1136\/bcr-2018-227951","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T08:58:04Z","timestamp":1556528284000},"page":"e227951","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Detection of a new melanoma in a patient treated with fingolimod"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6429-6363","authenticated-orcid":false,"given":"Yves","family":"Michiels","sequence":"first","affiliation":[{"name":"Center for Primary Care and Public Health (Unisant\u00e9), University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bugnon","sequence":"additional","affiliation":[{"name":"Center for Primary Care and Public Health (Unisant\u00e9), University of Lausanne, Lausanne, Switzerland"},{"name":"Community Pharmacy Unit, Pharmaceutical Sciences section, Universities of Geneva and Lausanne, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Michiels","sequence":"additional","affiliation":[{"name":"Laboratoire Central d\u2019Anatomie et Cytologie Pathologique, Centre Hospitalier Universitaire de Nice, H\u00f4pital Pasteur, CHU Nice, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Mazellier","sequence":"additional","affiliation":[{"name":"Laboratoire Central d\u2019Anatomie et Cytologie Pathologique, Centre Hospitalier Universitaire de Nice, H\u00f4pital Pasteur, CHU Nice, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"key":"2025082711523769000_12.4.e227951.1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1212\/WNL.0000000000004293","article-title":"Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS","volume":"89","author":"Killestein","year":"2017","journal-title":"Neurology"},{"key":"2025082711523769000_12.4.e227951.2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/cam4.1098","article-title":"Melanoma complicating treatment with natalizumab for multiple sclerosis: a report from the Southern Network on Adverse Reactions (SONAR)","volume":"6","author":"Sabol","year":"2017","journal-title":"Cancer Med"},{"key":"2025082711523769000_12.4.e227951.3","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs"},{"key":"2025082711523769000_12.4.e227951.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02552.x"},{"key":"2025082711523769000_12.4.e227951.5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/ced.12770","article-title":"Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis","volume":"41","author":"Haebich","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"2025082711523769000_12.4.e227951.6","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.212"},{"key":"2025082711523769000_12.4.e227951.7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jns.2017.09.003","article-title":"Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod","volume":"381","author":"Calvi","year":"2017","journal-title":"J Neurol Sci"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-227951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:52:42Z","timestamp":1756320762000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-227951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":7,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,29]]},"published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1136\/bcr-2018-227951"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-227951","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}